Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

Core Viewpoint - MDxHealth reported strong financial results for Q3 2025, with an 18% increase in revenues and a positive adjusted EBITDA of $1 million, alongside the strategic acquisition of Exosome Diagnostics from Bio-Techne Corporation [1][2][3]. Financial Performance - Q3 revenues reached $27.4 million, an 18% increase from $23.3 million in the same period last year [5][6]. - Year-to-date revenue growth was 20%, totaling $78.3 million compared to $65.3 million in the prior year [10][11]. - Gross profit for Q3 increased by 25% to $17.9 million, with gross margins improving to 65.2% from 61.2% [8][9]. - Operating expenses remained flat at $20.5 million, despite $1.5 million in acquisition-related expenses [9][11]. - The net loss for Q3 decreased by 28% to $8.0 million, compared to $11.2 million in the prior year [9][12]. Strategic Developments - The acquisition of Exosome Diagnostics was completed on September 15, 2025, which is expected to enhance the company's product offerings and sales capabilities [3][4]. - The company plans to focus on integrating the ExoDx business and has expanded its direct sales team from 50 to 60 representatives to leverage cross-selling opportunities [3][4]. - The introduction of germline products has been suspended to allocate resources towards ExoDx, Confirm, and GPS, with a reevaluation planned for 2026 [3][4]. Future Outlook - MDxHealth reaffirmed its full-year revenue guidance of $108 million to $110 million, expecting Q4 growth to meet or exceed 20% [4][12]. - The company reported a positive adjusted EBITDA of $1 million for Q3, marking a significant improvement from a loss of $3.9 million in the prior year [10][12].